{
    "clinical_study": {
        "@rank": "45437", 
        "brief_summary": {
            "textblock": "The objectives of this study are to determine the response rate to 9-AC in patients with\n      advanced ovarian cancer who have recurrent disease after paclitaxel- and cisplatin-based\n      chemotherapy regimens."
        }, 
        "brief_title": "A Phase II Trial of 72-Hour Continuous IV Infusion of 9-Aminocamptothecin With G-CSF Support in Patients With Advanced Ovarian Cancer Previously Treated With Paclitaxel and Cisplatin", 
        "completion_date": "April 2000", 
        "condition": "Ovarian Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Ovarian Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a Phase II study of 9-aminocamptothecin (9-AC), administered as an intravenous\n      continuous infusion over 72 hours with G-CSF support for patients with advanced refractory\n      ovarian cancer.  The objectives of the present study are to determine the response rate to\n      9-AC in patients with advanced ovarian cancer who have recurrent disease after paclitaxel-\n      and cisplatin-based chemotherapy regimens."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n        Histologically proven, advanced epithelial ovarian cancer.\n\n        Histologic confirmation by Pathology Department, NIH, required.\n\n        Recurrent disease after paclitaxel and either cisplatin or carboplatin. Combination\n        platinum/paclitaxel acceptable.\n\n        Bidimensionally measurable disease on physical exam, radiographs, or peritoneoscopy.\n        Repeat peritoneoscopy after 8 courses of therapy required if documentation of disease was\n        solely by peritoneoscopy.\n\n        Laparotomy not required.\n\n        No CNS metastasis.\n\n        No borderline or mixed histology.\n\n        PRIOR/CONCURRENT THERAPY:\n\n        See Disease Characteristics.\n\n        More than 4 weeks since any prior therapy and recovered.\n\n        No prior camptothecin analogue-based chemotherapy.\n\n        No prior radiotherapy except intraperitoneal 32-P.\n\n        PATIENT CHARACTERISTICS:\n\n        Age: 18 and over.\n\n        Performance status: ECOG 0-2.\n\n        Hematopoietic:\n\n        WBC greater than 3,000.\n\n        AGC greater than 1,500.\n\n        Platelets at least 100,000.\n\n        Hemoglobin greater than 9 g/dL OR;\n\n        Hematocrit greater than 27 g/dL.\n\n        Hepatic:\n\n        Bilirubin no greater than 1.5 mg/dL.\n\n        Serum transaminases no greater than 2 times normal.\n\n        Renal:\n\n        24-hour creatinine clearance greater than 45 mL/min (documented by NCI investigator or\n        primary care physician).\n\n        Cardiovascular:\n\n        No myocardial infarction within 12 months.\n\n        No active congestive heart failure.\n\n        No heart block.\n\n        No arrhythmia requiring medication.\n\n        OTHER:\n\n        No active uncontrolled infection.\n\n        No known HIV positivity.\n\n        No second malignancy currently under treatment except: Local basal cell carcinoma of the\n        skin, Cervical carcinoma in situ, Other malignancies (e.g., stage I breast cancer)\n        eligible at the discretion of the principal or associate investigators.\n\n        No pregnant women."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "40", 
        "firstreceived_date": "November 3, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001427", 
            "org_study_id": "950056", 
            "secondary_id": "95-C-0056"
        }, 
        "intervention": {
            "intervention_name": "9-aminocamptothecin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "9-amino-20-camptothecin", 
                "Cisplatin", 
                "Paclitaxel", 
                "Camptothecin"
            ]
        }, 
        "keyword": [
            "Pharmacodynamic Studies", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "March 3, 2008", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892"
                }, 
                "name": "National Cancer Institute (NCI)"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II Trial of 72-Hour Continuous IV Infusion of 9-Aminocamptothecin With G-CSF Support in Patients With Advanced Ovarian Cancer Previously Treated With Paclitaxel and Cisplatin", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "reference": [
            {
                "PMID": "1334279", 
                "citation": "Burris HA, Rothenberg ML, Kuhn JG, Von Hoff DD. Clinical trials with the topoisomerase I inhibitors. Semin Oncol. 1992 Dec;19(6):663-9. Review."
            }, 
            {
                "PMID": "1309380", 
                "citation": "Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol. 1992 Jan;10(1):16-20."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001427"
        }, 
        "source": "National Institutes of Health Clinical Center (CC)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "January 1995", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2000"
    }, 
    "geocoordinates": {
        "National Cancer Institute (NCI)": "38.985 -77.095"
    }
}